ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 495,13
0,46%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) Actualités

BCRX BioCryst Pharmaceuticals Inc

6,17
-0,06 (-0,96%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
BioCryst Pharmaceuticals Inc BCRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,06 -0,96% 6,17 06:00:08
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
6,13 5,995 6,20 6,17 6,23
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:08EDGAR2Form 144 - Report of proposed sale of securities
13/6/202422:23EDGAR2Form 8-K - Current report
04/6/202413:00GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
03/6/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/6/202410:00GLOBEBioCryst Presents New Real-world Evidence Showing Reductions..
31/5/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202413:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202413:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202413:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202413:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202413:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202413:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202413:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202413:00GLOBEBioCryst to Present New Data at 2024 Meeting of the European..
13/5/202413:00GLOBEORLADEYO® (berotralstat) Approved in Mexico
09/5/202413:00GLOBEBioCryst Presents New Real-world Evidence Showing..
07/5/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:00GLOBEBioCryst to Present at Upcoming Investor Conferences
06/5/202413:03EDGAR2Form 8-K - Current report
06/5/202413:00GLOBEBioCryst Reports First Quarter 2024 Financial Results and..
03/5/202413:00GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
22/4/202413:00GLOBEBioCryst to Report First Quarter 2024 Financial Results on..
17/4/202410:30GLOBEBioCryst Announces Approval of ORLADEYO® (berotralstat) by..
03/4/202413:00GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
25/3/202421:01GLOBEBioCryst to Present at Upcoming Investor Conferences
05/3/202413:01GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
04/3/202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:05EDGAR2Form S-3ASR - Automatic shelf registration statement of..
26/2/202413:05EDGAR2Form 8-K - Current report
26/2/202413:00GLOBEBioCryst Reports Fourth Quarter and Full Year 2023 Financial..
26/2/202411:57IHMARKETNEWSU.S. Index Futures Dip Amid Inflation Data Anticipation, Oil..
23/2/202413:00GLOBEBioCryst Presents New Real-world Data Showing Rapid,..
21/2/202422:01GLOBEBioCryst to Present at Upcoming Investor Conferences
19/2/202413:54GLOBEBioCryst Launches ORLADEYO® (berotralstat) in Italy
14/2/202422:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:02EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202413:00GLOBEBioCryst to Report Fourth Quarter 2023 Financial Results on..
05/2/202413:00GLOBEBioCryst to Present New ORLADEYO® (berotralstat) Real-world..

Dernières Valeurs Consultées

NASDAQ
BCRX
BioCryst Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés